Pacific Edge hails ‘huge achievement’

David Darling
David Darling
Shares in Pacific Edge doubled in price on Friday after the bladder cancer diagnostics provider said it had gained approval from United States regulators to get reimbursement from US health insurers for its Cxbladder cancer diagnostic tests.

This includes reimbursement for all Cxbladder tests performed for patients covered by the Centres for Medicare and Medicaid Services (CMS) across the US, at the already determined national CMS price for Cxbladder of $US760 ($NZ1162) per test, the Dunedin-based company said in a statement to the NZX.

The shares jumped 28c or 103% to 55c on the news.

The CMS provides healthcare coverage for all US citizens over 65 years, as well as assistance for healthcare coverage to people with low incomes.

CMS tests make up approximately 40% of Pacific Edge's current commercial tests in the US and the company said it would also be seeking to negotiate reimbursement for the Cxbladder tests that had previously been completed and invoiced for CMS patients.

"This is a transformational milestone for Pacific Edge and the result of a number of years of hard work and effort from our teams in New Zealand and the USA," Pacific Edge chief executive David Darling said.

"This long-awaited outcome results from the generation of substantial clinical evidence, publication of numerous clinical papers demonstrating the compelling clinical utility and outperformance of Cxbladder, and growing commercial use of our tests by urologists in the USA and other markets.

"Coverage under the LCD [local coverage determination] for our two Cxbladder tests with CPT [current procedural terminology] codes will unlock access to the CMS revenue which currently represents approximately 40% of Pacific Edge's commercial sales in the US.

The coverage decision was also expected to positively impact on demand and positive reimbursement decisions from other healthcare organisations and payers as well, Mr Darling said.

"It signals a new phase in Pacific Edge's commercial journey and we will be pushing hard on the back of this announcement to gain adoption of Cxbladder by other large-scale healthcare organisations."

Pacific Edge chairman Chris Gallaher said the LCD coverage signalled "a major step change" for the company.

"For a company from New Zealand, this is a huge achievement and one of which we are very proud."

Last month, one of the largest non-profit healthcare providers in the US approved commercial use of Pacific Edge’s Cxbladder kits.

Kaiser Permanente has more than 12 million members, operates 39 hospitals and employs about 23,000 physicians.

 — The New Zealand Herald/Additional reporting Otago Daily Times

Add a Comment






Our journalists are your neighbours

We are the South's eyes and ears in crucial council meetings, at court hearings, on the sidelines of sporting events and on the frontline of breaking news.

As our region faces uncharted waters in the wake of a global pandemic, Otago Daily Times continues to bring you local stories that matter.

We employ local journalists and photographers to tell your stories, as other outlets cut local coverage in favour of stories told out of Auckland, Wellington and Christchurch.

You can help us continue to bring you local news you can trust by becoming a supporter.

Become a Supporter